User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 4 results.
    • Speech
    Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up.
    Solal-Celigny, P. Imrie, K Belch, A Robinson, KS Cunningham, D. Rueda, A Catalano, J Offner, F. Walewski, J Raposo, J Smith, P. Marcus, R (2005) 47th Annual Meeting of the American-Society-of-Hematology — Atlanta(Ga)
    • Speech
    An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.
    Marcus, R Imrie, K Belch, A Cunningham, D. Flores, E Catalano, J Solal-Celigny, P. Offner, F. Walewski, J Raposo, J Jack, A Smith, P. (2003) 45th Annual Meeting of the American-Society-of-Hematology — SAN DIEGO(California)
    • Journal article
    Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Tilly, H Gomes da Silva, M Vitolo, U Jack, A Meignan, M Lopez-Guillermo, A Walewski, J André, Marc[UCL] Johnson, P W Pfreundschuh, M Ladetto, M ESMO Guidelines Committee (2015) Annals of Oncology — Vol. 26, no.suppl 5, p. v116-v125 (2015)
    • Journal article
    CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R Imrie, K Belch, A Cunningham, D. Flores, E Catalano, J Solal-Celigny, P. Offner, F. Walewski, J Raposo, J Jack, A Smith, P. (2005) Blood — Vol. 105, no. 4, p. 1417-1423 (2005)